Her-2/neu gene amplification and over-expression in stomach and esophageal adenocarcinoma: From pathology to treatment

Critical Reviews in Oncology/Hematology

Volumn 82, Issue 3, 2012, Pages 310-322

  Maresch, Judith ^a   Schoppmann, Sebastian F ^a,b   Thallinger, Christiane M R ^a,b   Zielinski, Christoph C ^a,b   Hejna, Michael ^a,b  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Amplification; Esophageal cancer; Her 2 neu; Over expression; Stomach cancer

Indexed keywords

BEVACIZUMAB; BRIVANIB ALANINATE; CAPECITABINE; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ERLOTINIB; FLUOROPYRIMIDINE; FLUOROURACIL; FORETINIB; GEFITINIB; INTERLEUKIN 12; LAPATINIB; LINSITINIB; MATUZUMAB; MONOCLONAL ANTIBODY; OXALIPLATIN; PACLITAXEL; SEMAXANIB; SORAFENIB; SUNITINIB; TRASTUZUMAB; VATALANIB;

ADJUVANT THERAPY; ADVANCED CANCER; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CARCINOMA CELL; CARDIOTOXICITY; DRUG POTENTIATION; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS BIOPSY; GENE; GENE AMPLIFICATION; GENE FUNCTION; GENE LOCATION; GENE OVEREXPRESSION; GENE TARGETING; HER 2 GENE; HUMAN; IMMUNOHISTOCHEMISTRY; LOADING DRUG DOSE; METASTASIS; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN LOCALIZATION; PROTEIN TARGETING; REGULATOR GENE; REVIEW; STOMACH ADENOCARCINOMA; STOMACH BIOPSY; STOMACH CANCER; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; ESOPHAGEAL NEOPLASMS; GENE AMPLIFICATION; GENE EXPRESSION; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; RECEPTOR, ERBB-2; STOMACH NEOPLASMS;

EID: 84861189123     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2011.06.003     Document Type: Review

References (103)

1. Comella P., Franco L., Casaretti R., de Portu S., Menditto E. Emerging role of capecitabine in gastric cancer. Pharmacotherapy 2009, 29:318-330.
2. Kamangar F., Dores G.M., Anderson W.F. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006, 24:2137-2150.
3. Ohtsu A. Chemotherapy for metastatic gastric cancer: past, present, and future. Gastroenterology 2008, 43:256-264.
4. Cunningham D., Starling N., Rao S., et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008, 358:36-46.
5. Yarden Y., Ullrich A. Growth factor receptor tyrosine kinases. Ann Rev Biochem 1988, 57:443-478.
6. Schechter A.L., Stern D.F., Vaidyanathan L., et al. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 1984, 312:513-516.
7. King C.R., Kraus M.H., Aaronson S.A. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 1985, 229:974-976.
8. Yamamoto T., Ikawa S., Akiyama T., et al. Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature 1986, 319:230-234.
9. Yokota J., Yamamoto T., Toyoshima K., et al. Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo. Lancet 1986, 1:765-767.
10. Slamon D.J., Godolphin E., Jones L.A., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244:7007-7012.
11. Morris M.J., Reuter V.E., Kelly W.K., et al. HER-2 prolining and targeting in prostate carcinoma. Cancer 2002, 94:980-986.
12. Schuell B., Gruenberger T., Scheithauer W., Zielinski C.C., Wrba F. HER2/neu protein expression in colorectal cancer. BMC Cancer 2006, 123:1-5.
13. Safran H., Steinhoff M., Mangray S.R., et al. Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma. Am J Clin Oncol 2001, 24:496-499.
14. Schoppmann S.F., Jesch B., Friedrich J., et al. Expression of Her-2 in carcinomas of the esophagus. Am J Surg Pathol 2010, 34:1868-1873.
15. Bang Y.J., Van Cutsem E., Feyereislova A., et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010, 376:687-697.
16. Al-Kasspooles M., Moore J.H., Orringer M.B., Beer D.G. Amplification and over-expression of the EGFR and erbB-2 genes in human esophageal adenocarcinomas. Int J Cancer 1993, 54(2):213-219.
17. Ross J.S., McKenna B.J. The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest 2001, 19(5):554-568.
18. Ross J.S., Slodkowska E.A., Symmans W.F.L., Pusztai L., Ravdin P.M., Hortobagyi G.N. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009, 14:320-368.
19. Jørgensen J.T., Nielsen K.V., Ejlertsen B. Pharmacodiagnostics and targeted therapies: a rational approach for individualizing medical anti-cancer therapy in breast cancer. Oncologist 2007, 2:397-405.
20. Yonemura Y., Ninomiya I., Yamaguchi A., et al. Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. Cancer Res 1991, 51:1034-1038.
21. Roh J.K., Paik S., Chun H.C., et al. Overexpression of erbB-2 protein in gastric adenocarcinoma: a potential role in therapeutic response to adjuvant 5-FU-doxorubicin regimen. Jpn J Cancer Chemother 1992, 19:1207-1219.
22. Tateishi M., Toda T., Minamisono Y., Nagasaki S. Clinicopathological significance of c-erbB-2 protein expression in human gastric carcinoma. J Surg Oncol 1992, 49:209-212.
23. Yonemura Y., Ninomiya I., Ohoyama S., et al. Correlation of c-erbB-2 protein expression and lymph node status in early gastric cancer. Oncology 1992, 49:363-367.
24. Ohguri T., Sato Y., Koizumi W., Saigenji K., Kameya T. An immunohistochemical study of c-erbB-2 protein in gastric carcinomas and lymph-node metastases: is the c-erbB-2 protein really a prognostic indicator?. Int J Cancer 1993, 53:75-79.
25. Mizutani T., Onda M., Tokunaga A.K., Sonoda K., Shiraishi N., Kitano S. Relationship of C-erbB-2 protein expression and gene amplification to invasion and metastasis in human gastric cancer. Cancer 1993, 72:2083-2088.
26. Motojima K., Furui J., Kohara N.N., Yamanaka N., Sugisaki Y. erbB-2 expression in well-differentiated adenocarcinoma of the stomach predicts shorter survival after curative resection. Surgery 1994, 115:349-354.
27. Lee H.R., Kim J.H., Uhm H.D., et al. Overexpression of c-ErbB-2 protein in gastric cancer by immunohistochemical stain. Oncology 1996, 53:192-197.
28. Shun C.T., Wu M.S., Lin J.T., et al. Relationship of p53 and c-erbB-2 expression to histopathological features. Helicobacter pylori infection and prognosis in gastric cancer. Hepatogastroenterology 1996, 44:604-609.
29. Ishikawa T., Kobayashi M., Mai M., Suzuki, Ooi A. Amplification of c-erbB-2(HER2/neu) gene in gastric cancer cells. Am J Pathol 1997, 151:761-768.
30. Wu M.S., Shun C.T., Wang H.P., et al. Genetic alterations in gastric cancer: relation to histological subtypes, tumor stage, and Helicobacter pylori infection. Gastroenterology 1997, 112:1457-1465.
31. Ooi A., Kobayashi M., Mai M.I, Nakanishi I. Amplification of c-erbB-2 in gastric cancer: detection in formalin-fixed, paraffin-embedded tissue by fluorescence in situ hybridization. Lab Invest 1998, 78:345-351.
32. Nakajima M., Sawada H., Yamada Y., et al. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 1999, 85:1894-1902.
33. Allgayer H., Babic R., Gruetzner K.U., Tarabichi A., Schildberg F.W., Heiss M.M. c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J Clin Oncol 2000, 18:2201-2209.
34. Ougolkov A., Mai M., Takahashi Y., et al. Altered expression of beta-catenin and c-erbB-2 in early gastric cancer. J Exp Clin Cancer Res 2000, 19:349-355.
35. Sanz-Ortega J., Steinberg S.M., Moro E., et al. Comparative study of tumor angiogenesis and immunohistochemistry for p53, c-ErbB2, c-myc and EGFr as prognostic factors in gastric cancer. Histol Histopathol 2000, 15:455-462.
36. Wang Y.L., Sheu B.S., Yang H.B., Lin P.W., Chang Y.C. Overexpression of c-erb-B2 proteins in tumor and non-tumor parts of gastric adenocarcinoma: emphasis on its relation to H. pylori infection and clinicohistological characteristics. Hepatogastroenterology 2002, 49:1172-1176.
37. Ghaderi A., Vasei M., Maleck-Hosseini S.A., et al. The expression of c-erbB-1 and c-erbB-2 in Iranian patients with gastric carcinoma. Pathol Oncol Res 2002, 8:252-256.
38. Takehana T., Kunitomo K., Kono K., et al. Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay. Int J Cancer 2002, 98:833-837.
39. Pinto-de-Sousa J., David L., Almeida R., et al. c-erb B-2 expression is associated with tumor location and venous invasion and influences survival of patients with gastric carcinoma. Int J Surg Pathol 2002, 10:247-256.
40. Lee K.E., Lee H.J., Kim Y.H., et al. Prognostic significance of p53, nm23, PCNA and c-erbB-2 in gastric cancer. Jpn J Clin Oncol 2003, 33:173-179.
41. Tanner M., Hollmén M., Junttila T.T., et al. Amplification of HER-2 in gastric carcinoma: association with topoisomerase II alpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005, 16:273-278.
42. Yano T., Doi T., Ohtsu A., et al. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep 2006, 5:65-71.
43. Dreilich M., Wanders A., Brattström D., et al. HER-2 overexpression (3+) in patients with squamous cell esophageal carcinoma correlates with poorer survival. Dis Esophagus 2006, 19(4):224-231.
44. Park D.I., Yun J.W., Park J.H., et al. Her2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 2006, 51:1371-1379.
45. Langer R., Von Rahden B.H., Nahrig J., et al. Prognostic significance of expression patterns of c-erbB-2, p53, p16INK4A, p27KIP1, cyclin D1 and epidermal growth factor receptor in oesophageal adenocarcinoma: a tissue microarray study. J Clin Pathol 2006, 59:631-634.
46. Reichelt U., Duesedau P., Tsourlakis M.C., et al. Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol 2007, 20:120-129.
47. Hofmann M., Stoss O., Shi D., et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008, 52:797-805.
48. Barros-Silva J.D., Leitão D., Afonso L., et al. Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer 2009, 100:487-493.
49. Marx A.H., Tharun L., Muth J., et al. HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol 2009, 40:769-777.
50. Yu G.Z., Chen Y., Wang J.J. Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance. J Cancer Res Clin Oncol 2009, 135:1331-1339.
51. Zhang X.L., Yang Y.S., Xu D.P., et al. Comparative study on overexpression of HER2/neu and HER3 in gastric cancer. World J Surg 2009, 33:2112-2118.
52. Sato-Kuwabara Y., Neves J.I., Fregnani J.H., Sallum R.A., Soares F.A. Evaluation of gene amplification and protein expression of HER-2/neu in esophageal squamous cell carcinoma using Fluorescence in situ Hybridization (FISH) and immunohistochemistry. BMC Cancer 2009, 9:6.
53. Grabsch H., Sivakumar S., Gray S., Gabbert H.E., Muller W. HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series. Cell Oncol 2010, 32:57-65.
54. Vincent-Salomon A., Pierga J.Y., Couturier J., et al. HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management?. Br J Cancer 2007, 96:654-659.
55. Lottner C., Schwarz S., Diermeier S., et al. Simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin-embedded breast cancer. J Pathol 2005, 205:577-584.
56. O'Malley P.F., Thomson T., Julian J., et al. HER2 testing in a population-based study of patients with metastatic breast cancer treated with trastuzumab. Arch Pathol Lab Med 2008, 132:61-65.
57. Rüschoff J., Dietel M., Baretton G., et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch 2010, 457(3):299-307.
58. Hudis C.A. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007, 357(1):39-51.
59. Tai J., Cheung S., Chan E. Inhibition of breast cancer cell growth and invasiveness by dual silencing of HER-2 and VEGF. Mol Pharm 2010, 7:543-556.
60. Burstein H.J. The distinctive nature of HER2-positive breast cancers. N Engl J Med 2005, 353:1652-1654.
61. Gschwind A., Fischer O.M., Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 2004, 4(5):361-370.
62. Kasprzyk P.G., Song S.U., Di Fiore P.P., King C.R. Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies. Cancer Res 1992, 52:2771-2776.
63. Kim S.Y., Kim H.P., Kim Y.J., et al. Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin. Int J Oncol 2008, 32:89-95.
64. Matsui Y., Inomata M., Tojigamori M., Sonoda K., Shiraishi N., Kitano S. Suppression of tumor growth in human gastric cancer with HER2 over-expression by an anti-HER2 antibody in a murine model. Int J Oncol 2005, 27:681-685.
65. Fujimoto-Ouchi K., Sekiguchi F., Yasuno H., Moriya Y., Mori K., Tanaka Y. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother Pharmacol 2007, 59:795-805.
66. Nicholas G., Cripps C., Au H.J., et al. Early results of a trial of trastuzumab, cisplatin and docetaxel for the treatment of metastatic gastric cancer over-expressing HER-2. Ann Oncol 2006, 17:1105.
67. Rech J., Arnold D., Folprecht G., Hejna M., Hofmann M., Gramatzki M. A pilot study of trastuzumab monotherapy in patients who progressed while on chemotherapy for metastatic or locally advanced HER-2 positive gastric cancer. Ann Oncol 2006, 17:1096.
68. Cortés-Funes H., Rivera F., Alés I., et al. Phase II of trastuzumab and cisplatin in patients (pts) with advanced gastric cancer (AGC) with HER2/neu overexpression/amplification. J Clin Oncol 2007, 25:4613.
69. McKeage K., Perry C.M. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs 2002, 62:209-243.
70. Garnock-Jones K.P., Keating G.M., Scott L.J. Trastuzumab: a review of its use as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. Drugs 2010, 70:215-239.
71. Harbeck N, Ewer MS, De Laurentiis M, Suter TM, Ewer SM. Cardiovascular complications of conventional and targeted adjuvant breast cancer therapy. Ann Oncol, in press.
72. Cunningham D., Allum W.H., Stenning S.P., et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. New Engl J Med 2006, 355:11-20.
73. Untch M., Muscholl M., Tjulandin S., et al. First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the herceptin, cyclophosphamide, and epirubicin (HERCULES) trial. J Clin Oncol 2010, 28:1473-1480.
74. Billingham M.E., Mason J.W., Bristow M.R., Daniels J.R. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep 1978, 62:865-872.
75. Mackay B., Ewer M.S., Carrasco C.H., Benjamin R.S. Assessment of anthracycline cardiomyopathy by endomyocardial biopsy. Ultrastruct Pathol 1994, 18:203-211.
76. Singal P.K., Iliskovic N. Doxorubicin-induced cardiomyopathy. New Engl J Med 1998, 339:900-905.
77. Ryberg M., Nielsen D., Skovsgaard T.J., Hansen, Jensen B.V., Dombernowsky P. Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. J Clin Oncol 1998, 16:3502-3508.
78. Seidman A., Hudis C., Pierri M.K., et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002, 20:1215-1221.
79. Ewer M.S., Vooletich M.T., Durand J.B., et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 2005, 23:7820-7826.
80. Wainberg Z.A., Anghel A., Desai A.J., et al. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. Clin Cancer Res 2010, 16:1509-1519.
81. Kim J.W., Kim H.P., Im S.A., et al. The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines. Cancer Lett 2008, 272:296-306.
82. Iqbal S.B., Goldman H.J., Lenz C.M., Fenoglio-Preiser C.M., Blanke C.D. S0413: a phase II SWOG study of GW572016 (lapatinib) as first line therapy in patients (pts) with advanced or metastatic gastric cancer. J Clin Oncol 2007, 25:4621.
83. Hecht J.R., Urba S.G., Koehler M., et al. Lapatinib monotherapy in recurrent upper gastrointestinal malignancy: phase II efficacy and biomarker analyses. J Clin Oncol 2008, 34:43.
84. Galsky M.D., Von Hoff D.D., Neubauer M., et al. Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors. J Clin Oncol 2009, 27:3541.
85. NCT01220934. Clinical Practice Surveillance of the Use of Herceptin in Patients with HER2-positive Advanced Adenocarcinoma of the Stomach or Gastro-esophageal Junction (GEJ) (HERMES). , ClinicalTrials.gov Identifier: NCT01220934. http://www.clinicaltrial.gov/.
86. NCT01260194. An Open-label, Multicentre Phase IV Study of Trastuzumab in Combination with the Standard Therapy (as Per Routine Clinical Practice) as First-line Therapy in Patients with HER2 Positive Metastatic Gastric Cancer. , ClinicalTrials.gov Identifier: NCT01260194. http://www.clinicaltrial.gov/.
87. NCT01191697. Phase II Trial of CAPOX, Bevacizumab and Trastuzumab for Patients with HER2-Positive Metastatic Esophagogastric Cancer. , ClinicalTrials.gov Identifier: NCT01191697. http://www.clinicaltrial.gov/.
88. NCT00486954. A Randomized, Multicenter, Open-label, Phase III Study of Lapatinip in Combination with Weekly Paclitaxel Versus Weekly Paclitaxel Alone in the Second Line Treatment of ErbB2 Amplified Advanced Gastric Cancer. , ClinicalTrials.gov Identifier: NCT00486954. http://www.clinicaltrial.gov/.
89. NCT00680901. A Phase III Study for ErbB2 Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Junction Adenocarcinoma Treated With Capecitabine Plus Oxaliplatin with or without Lapatinip. , ClinicalTrials.gov Identifier: NCT00680901. http://www.clinicaltrial.gov/.
90. NCT00103324. Phase II Study of GW572016 (NSC #727989) as First Line Therapy in Patients With Advanced or Metastatic Gastric Cancer. , ClinicalTrials.gov Identifier: NCT00103324. http://www.clinicaltrial.gov/.
91. NCT00259987. A Phase II, Open-Label Study Evaluating Clinical Efficacy, Safety, Pharmacokinetic and Pharmacodynamic Effects of Lapatinip in Patients With Relapsed Adenocarcinoma of the Esophagus, Including Tumors of the Gastroesophageal Junction and Gastric Cardia. , ClinicalTrials.gov Identifier: NCT00259987. http://www.clinicaltrial.gov/.
92. NCT00239200. Lapatinip a Dual Inhibitor of EGFR and ErbB2, for Metastatic or Recurrent Squamous Cell Carcinoma of the Esophagus. , ClinicalTrials.gov Identifier: NCT00239200. http://www.clinicaltrial.gov/.
93. NCT00526669. An Exploratory, Phase II Trial to Determine the Association of Lapatinip Induced Fluoropyrimidine Gene Changes with Efficacy Parameters of Lapatinip and Capecitabine in First Line Gastric Cancer. , ClinicalTrials.gov Identifier: NCT00526669. http://www.clinicaltrial.gov/.
94. NCT01123473. Effectiveness of First Line Treatment with Lapatinip and ECF/X in Histologically Proven Adenocarcinoma of the Stomach or the Esophagogastric Junction, Metastatic or Not Amenable to Curative Surgery According to HER2 and EGFR Status: a Randomized Phase II Trial. , ClinicalTrials.gov Identifier: NCT01123473. http://www.clinicaltrial.gov/.
95. NCT01145404. Lapatinip Versus Lapatinip with Capecitabine as Second-line Treatment in Her2-Overexpressing Metastatic Gastro-Esophageal Cancer: A Randomized Phase II Trial. , ClinicalTrials.gov Identifier: NCT01145404. http://www.clinicaltrial.gov/.
96. Safran H., Dipetrillo T., Akerman P., et al. Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma. Int J Radiat Oncol Biol Phys 2007, 67:405-409.
97. Bekaii-Saab T.S., Roda J.M., Guenterberg K.D., et al. A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies. Mol Cancer Ther 2009, 8:2983-2991.
98. Egamberdiev D.M., Djuraev M.D., Tuydjanova K., Nematov O.N. Our experience in the use of trastuzumab in patients with advanced stomach cancer. Ann Oncol 2010, 839.
99. Hecht J., Bang Y., Sobrero A., et al. A phase III study of CapeOx +/- lapatinib in HER2 positive locally-advanced/metastatic upper gastrointestinal adenocarcinoma: interim safety results. Eur J Cancer 2009, 7:6584.
100. Satoh T., Bang Y., Wang J., et al. Interim safety analysis from TYTAN: a phase III Asian study of lapatinib in combination with paclitaxel as second-line therapy in gastric cancer. J Clin Oncol 2010, 28:4057.
101. Roth A., Moehler M.H., Mauer M., et al. Lapatinib in combination with ECF/X in EGFR1 or HER2-overexpressing first-line metastatic gastric cancer (GC): a phase II randomized placebo controlled trial (EORTC 40071). J Clin Oncol 2010, 28:205.
102. Ford H., Hochhauser D., Paterson A., et al. Phase Ib trial of lapatinib oxaliplatin and capecitabine in early HER2-overexpressing esophagogastric cancer. J Clin Oncol 2010, 28:339.
103. Pishvaian M., Sakaeva D., Hsieh R.K., et al. A global, multicenter phase II trial of lapatinib plus capecitabine in gastric cancer. J Clin Oncol 2011, 29:88.